PREVENTING ACUTE REJECTION, EPSTEIN-BARR VIRUS INFECTION, AND POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AFTER KIDNEY TRANSPLANTATION: USE OF ACICLOVIR AND MYCOPHENOLATE MOFETIL IN A STEROID-FREE IMMUNOSUPPRESSIVE PROTOCOL1

Abstract

Supplemental immunosuppression with mofetil protects against acute rejection. In combination with aciclovir, there is also a reduction in the number of PREBVs, apparently as a result of both direct viral prophylaxis and better rejection control, and in the incidence of EBV-induced PTLD.